Lasmiditan (REYVOW) is a drug used in the termination of migraine headaches approved by FDA in October 2019. It is a highly selective agonist of 5-HT1F receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for the adverse effects (e.g. vasoconstriction) of its predecessors. Part of this molecule is a piperidine carboxylic acid – popular fragment in Drug Discovery. We have created a set of in-stock piperidine carboxylic acids Building Blocks to generate new ideas for your projects.